文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

大流行期间中国及其他中低收入国家COVID-19患者抗生素处方率的系统综述与Meta分析(2019年12月至2021年3月)

Prevalence of antibiotic prescribing in COVID-19 patients in China and other low- and middle-income countries during the pandemic (December 2019-March 2021): a systematic review and meta-analysis.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该系统综述与Meta分析检索2019年12月1日至2021年3月31日五个数据库,纳入284项研究、19个国家210 611例COVID-19患者。中国住院患者抗生素处方率为71.7%(95%CI 66.7%-76.5%),其他中低收入国家为86.5%(77.1%-93.9%);轻/中症中国为66.9%(57.9%-75.4%),其他中低收入国家为91.8%(71.4%-100%)。作者结论为许多中低收入国家COVID-19住院患者存在不适当抗生素使用和高处方率。

要点

  • 中国COVID-19住院患者抗生素处方率为71.7%(95%CI 66.7%-76.5%)。
  • 其他中低收入国家住院患者抗生素处方率为86.5%(77.1%-93.9%)。
  • 中国轻/中症患者处方率66.9%,低于其他中低收入国家的91.8%。

核心结论

  • 许多中低收入国家COVID-19住院患者存在不适当抗生素使用和高抗生素处方率。

研究设计与样本

  • 系统综述与Meta分析,检索Web of Science、EMBASE、PubMed、中国知网(CNKI)和维普(VIP)数据库,时间范围为2019年12月1日至2021年3月31日。
  • 纳入报告至少10例COVID-19患者抗生素使用的干预性和观察性研究,不限研究场景,限制英文和中文文献。
  • 共纳入284项研究,涉及19个国家的210 611例参与者;由至少两名独立评审者进行筛选和数据提取,采用随机效应Meta分析合并结果,并用亚组分析和Meta回归探索异质性。
  • 本综述在PROSPERO注册(CRD42021288291)。

主要发现

  • 中国COVID-19住院患者抗生素处方率为71.7%(95%CI 66.7%-76.5%),其他中低收入国家为86.5%(77.1%-93.9%)。
  • 中国轻/中症病例抗生素处方率为66.9%(57.9%-75.4%),其他中低收入国家为91.8%(71.4%-100%)。
  • 中国孕妇和老年人中观察到高抗生素处方率,其他患者组间抗生素处方率存在差异。
  • 在报告细菌感染的研究中,中国细菌感染患病率为17.3%(10.0%-25.9%),其他中低收入国家为24.9%(0.1%-68.8%)。
  • 中低收入国家频繁处方WHO「观察」和「储备」清单中的多种抗生素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Low- and middle-income countries (LMICs) are particularly vulnerable to the threat of antimicrobial resistance (AMR). Use of antibiotics to treat COVID-19 patients during the pandemic may have contributed to increasing the AMR burden, but systematic evidence is lacking. METHODS: We searched Web of Science, EMBASE, PubMed, China National Knowledge Infrastructure (CNKI) and VIP databases from 1 December 2019 to 31 March 2021. Interventional and observation studies across all settings that reported antibiotic use in at least 10 COVID-19 patients were included. We restricted publications to English and Chinese languages. Screening and data extraction were undertaken by at least two independent reviewers. Results were synthesized using random-effects meta-analyses. Subgroup analyses and meta-regression were used to explore heterogeneities. This review was registered with PROSPERO (CRD42021288291). RESULTS: We included 284 studies involving 210 611 participants in 19 countries. The antibiotic prescribing rates (APRs) in COVID-19 inpatients were 71.7% (95% CI 66.7%-76.5%) in China and 86.5% (77.1%-93.9%) in other LMICs, respectively. APR was lower in mild/moderate cases in China [66.9% (57.9%-75.4%) compared with 91.8% (71.4%-100%) in other LMICs]. High APRs were found among pregnant women and the elderly in China. Disparities in APRs of other patient groups were identified. In studies reporting bacterial infections, the prevalence was 17.3% (10.0%-25.9%) in China and 24.9% (0.1%-68.8%) in other LMICs. Several antibiotics on the WHO 'Watch' and 'Reserve' lists were prescribed frequently in LMICs. CONCLUSIONS: Inappropriate antibiotic use and high prevalence of antibiotic prescribing were found in COVID-19 inpatients in many LMICs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Cong W, Cheng HY, Stuart B, et al. Prevalence of antibiotic prescribing in COVID-19 patients in China and other low- and middle-income countries during the pandemic (December 2019-March 2021): a systematic review and meta-analysis. J Antimicrob Chemother. 2023. PMID: 37883697. doi:10.1093/jac/dkad302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。